Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Int J Radiat Oncol Biol Phys ; 66(2): 345-51, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-16887287

ABSTRACT

PURPOSE: The aim of this study was to compare, on a retrospective basis, the results of therapy in patients with uveal hemangioma treated with photon or proton irradiation at a single center. METHODS: From 1993 to 2002 a total of 44 patients were treated. Until 1998 radiotherapy was given with 6 MV photons in standard fractionation of 2.0 Gy 5 times per week. In 1998 proton therapy became available and was used since then. A dose of 20 to 22.5 Cobalt Gray Equivalent (CGE) 68 MeV protons was given on 4 consecutive days. Progressive symptoms or deterioration of vision were the indications for therapy. RESULTS: Of the 44 patients treated, 36 had circumscribed choroidal hemangiomas and 8 had diffuse choroidal hemangiomas (DCH) and Sturge-Weber syndrome. Of the patients, 19 were treated with photons with a total dose in the range of 16 to 30 Gy. A total of 25 patients were irradiated with protons. All patients with DCH but 1 were treated with photons. Stabilization of visual acuity was achieved in 93.2% of all patients. Tumor thickness decreased in 95.4% and retinal detachment resolved in 92.9%. Late effects, although generally mild or moderate, were frequently detected. In all, 40.9% showed radiation-induced optic neuropathy, maximum Grade I. Retinopathy was found in 29.5% of cases, but only 1 patient experienced more than Grade II severity. Retinopathy and radiation-induced optic neuropathy were reversible in some of the patients and in some resolved completely. No differences could be detected between patients with circumscribed choroidal hemangiomas treated with protons and photons. Treatment was less effective in DCH patients (75%). CONCLUSIONS: Radiotherapy is effective in treating choroidal hemangiomas with respect to visual acuity and tumor thickness but a benefit of proton therapy could not be detected. Side effects are moderate but careful monitoring for side effects should be part of the follow-up procedures.


Subject(s)
Choroid Neoplasms/radiotherapy , Hemangioma/radiotherapy , Photons/therapeutic use , Proton Therapy , Adolescent , Adult , Atrophy/etiology , Cataract/etiology , Choroid Neoplasms/pathology , Hemangioma/pathology , Humans , Middle Aged , Optic Nerve/pathology , Optic Nerve/radiation effects , Photons/adverse effects , Protons/adverse effects , Radiotherapy Dosage , Retrospective Studies , Sturge-Weber Syndrome/radiotherapy , Treatment Outcome , Visual Acuity/radiation effects
2.
Strahlenther Onkol ; 182(7): 395-9, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16826358

ABSTRACT

BACKGROUND AND PURPOSE: Proton therapy for uveal melanoma provides high-conformal dose application to the target volume and, thus, an optimal saving of the organs at risk nearby. Treatment planning is done with the model-based treatment-planning system EYEPLAN. Tumor reconstruction is based only on a fundus composite, which often leads to an overestimation of the clinical target volume (CTV). The purpose was to exploit MRI on trial in a proton therapy-planning system by using the novel image-based treatment-planning system OCTOPUS. PATIENTS AND METHODS: Ten patients with uveal melanomas received both a high-resolution planning CT and MRI of the eye. MR examinations were made with an eye coil. EYEPLAN requires eye geometry data for modeling, and tantalum marker clips for submillimeter positioning and additional information from ultrasound and 3-D imaging. By contrast, OCTOPUS provides the full integration of 3-D imaging (e. g., CT, MRI). CTVs were delineated in each slice. For all patients, CTVs (EYEPLAN vs. OCTOPUS) were compared intraindividually. RESULTS: OCTOPUS planning led to a mean reduction of the target volume by a factor of 1.7 (T1-weighted [T1w]) and 2.2 (T2w) without compromising safety. The corresponding field size could be scaled down on average by a factor of 1.2 (T1w) and 1.4 (T2w), respectively. CONCLUSION: Compared with the conventional EYEPLAN, MRI-based treatment planning of ocular tumors with OCTOPUS could be a powerful tool for reducing the CTV and, consequently, the treatment volume and the field size. This might be translated into a better patient compliance during treatment and a decreased late toxicity.


Subject(s)
Magnetic Resonance Imaging , Melanoma/radiotherapy , Proton Therapy , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Computer-Assisted/methods , Uveal Neoplasms/radiotherapy , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Tomography, X-Ray Computed , Treatment Outcome
3.
Strahlenther Onkol ; 181(12): 783-8, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16362788

ABSTRACT

BACKGROUND AND PURPOSE: Proton and stereotactic radiotherapy with photons (SRT) are both used to treat choroidal melanomas in proximity to optic disk and fovea centralis, a situation where plaque therapy is prone to complications. A comparative treatment- planning study was done to assess the capability of both modalities to preserve vision. PATIENTS AND METHODS: In ten patients treated with 68-MeV protons, SRT with 6-MV photons was planned. Structures most important for visual acuity (fovea and optic disk, optic nerve) were contoured identically for both therapies. Safety margins of 1.5 mm for proton therapy were reduced to 1.0 mm for SRT. RESULTS: Proton-beam therapy was superior in eight of ten situations, and this result did not differ significantly by changes in the weighting of the different parameters analyzed. CONCLUSION: When dose deposition to those structures most important for the preservation of vision is taken into account, under the conditions examined proton therapy offers an advantage in the majority of the patients evaluated.


Subject(s)
Eye Injuries/prevention & control , Melanoma/therapy , Proton Therapy , Radiation Injuries/prevention & control , Radiosurgery/methods , Radiotherapy Planning, Computer-Assisted/methods , Uveal Neoplasms/therapy , Eye Injuries/etiology , Humans , Prognosis , Protons/adverse effects , Radiation Injuries/etiology , Radiometry/methods , Radiosurgery/adverse effects , Radiotherapy Dosage , Risk Assessment , Risk Factors , Treatment Outcome
4.
Strahlenther Onkol ; 180(7): 419-24, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15241529

ABSTRACT

BACKGROUND AND PURPOSE: In June 1998, proton-beam therapy of ocular tumors started at the Hahn-Meitner Institute Berlin, Germany. The purpose of the present study is to evaluate treatment outcome for uveal melanomas. PATIENTS AND METHODS: 245 consecutive patients with primary melanoma of the uvea were treated from June 1998 to April 2003 with a 68-MeV proton beam. In 96.2% of all patients, a uniform fractionation scheme was applied: single dose 15 CGE (cobalt gray equivalent), total dose 60 CGE on 4 consecutive days. Follow-up is available in 229 patients. RESULTS: At the time of median follow-up (18.4 months), local control is 96.4% and 95.5% at 3 years. Eye retention rate is 92.6% at 20 months (median follow-up) and 87.5% at 3 years. CONCLUSION: Proton-beam irradiation of uveal melanomas at the Hahn-Meitner Institute after the first 5 years of its initiation reveals local tumor control and eye retention rates in the range of other centers with larger experience. Delivering high treatment quality in hadron therapy from the beginning has been achieved.


Subject(s)
Melanoma/radiotherapy , Proton Therapy , Uveal Neoplasms/radiotherapy , Adolescent , Adult , Aged , Aged, 80 and over , Berlin , Dose Fractionation, Radiation , Eye Diseases/etiology , Follow-Up Studies , Glaucoma/etiology , Humans , Melanoma/pathology , Middle Aged , Neoplasm Recurrence, Local , Protons/adverse effects , Retrospective Studies , Time Factors , Treatment Outcome , Uveal Neoplasms/pathology
5.
Z Med Phys ; 14(1): 64-71, 2004.
Article in German | MEDLINE | ID: mdl-15104012

ABSTRACT

Eye tumors (choroidal melanomas, iris melanomas, and choroidal hemangiomas) are being treated with 68 MeV protons since 1998 at the Ion Beam Laboratory of the Hahn-Meitner Institute of Berlin (Germany's first proton therapy center), in cooperation with the Charité University Hospital in Berlin, Campus Benjamin Franklin. The proton beam, generated via a combination of Van de Graaff accelerator and cyclotron, is prepared by passive shaping for conformal tumor irradiation. A digital X-ray verification of the tumor location with the patient in sitting position limits the position uncertainties to a maximum of 0.3 mm. The treatment planning is performed using the program EYEPLAN. OCTOPUS, a CT-based planning program developed in cooperation with the German Cancer Research Center of Heidelberg, is under pre-clinical testing. Thus far, more than 400 patients have been irradiated. The first results are comparable to those obtained in other proton therapy centers. At the end of 2002, the University Hospital of Essen has also become a cooperation partner of the Hahn-Meitner Institute.


Subject(s)
Eye Neoplasms/radiotherapy , Proton Therapy , Academies and Institutes , Berlin , Choroid Neoplasms/radiotherapy , Cyclotrons , Hemangioma/radiotherapy , Hospitals, University , Humans , Image Processing, Computer-Assisted , Melanoma/radiotherapy , Particle Accelerators , Phantoms, Imaging , Radiotherapy Planning, Computer-Assisted , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...